Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product ...

It’s too early to say conclusively, but the market may be in the process of getting in front of this phase of the AI narrative, as small-cap stocks have recently been outperforming large-cap stocks.